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Abstract
Background: Duffy blood group polymorphisms are important in areas where Plasmodium vivax is present
because this surface antigen is thought to act as a key receptor for this parasite. In the present study, Duffy blood
group genotyping was performed in febrile uninfected and P. vivax-infected patients living in the city of
Nouakchott, Mauritania.
Methods: Plasmodium vivax was identified by real-time PCR. The Duffy blood group genotypes were determined
by standard PCR followed by sequencing of the promoter region and exon 2 of the Duffy gene in 277 febrile
individuals. Fisher’s exact test was performed in order to assess the significance of variables.
Results: In the Moorish population, a high frequency of the FYB
ES/FYB
ES genotype was observed in uninfected
individuals (27.8%), whereas no P. vivax-infected patient had this genotype. This was followed by a high level of
FYA/FYB, FYB/FYB, FYB/FYB
ES and FYA/FYB
ES genotype frequencies, both in the P. vivax-infected and uninfected
patients. In other ethnic groups (Poular, Soninke, Wolof), only the FYB
ES/FYB
ES genotype was found in uninfected
patients, whereas the FYA/FYB
ES genotype was observed in two P. vivax-infected patients. In addition, one patient
belonging to the Wolof ethnic group presented the FYB
ES/FYB
ES genotype and was infected by P. vivax.
Conclusions: This study presents the Duffy blood group polymorphisms in Nouakchott City and demonstrates that
in Mauritania, P. vivax is able to infect Duffy-negative patients. Further studies are necessary to identify the process
that enables this Duffy-independent P. vivax invasion of human red blood cells.
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Background
Malaria remains one of the most important parasitic
infections in the world, with almost 225 million cases of
infection and 0.78 million deaths in 2009, mainly in
Africa, Asia and South America [1]. It is caused by
infection with one or more of five species of Plasmo-
dium parasites. Plasmodium vivax is the second most
common cause of malaria in the world after Plasmo-
dium falciparum, with more than 80 million clinical
cases annually. Unlike P. falciparum, P. vivax rarely
causes mortality, but it can potentially lead to severe
complications and is thereby responsible for consider-
able morbidity and economic loss in endemic countries
[2-8]. Moreover, P. vivax has a wider geographical
range, potentially exposing more people to risk of infec-
tion (2.85 billion across three continents) [9-11], and it
is more difficult to control because of the hypnozoïte
forms of the parasite [12,13]. The presence of P. vivax
in Mauritania was first reported in 1948 [14]. More
recently, several studies conducted in Nouakchott, the
capital of Mauritania, revealed a high proportion of P.
vivax, followed by Plasmodium ovale and P. falciparum;
autochthonous malaria cases exist but are relatively
uncommon [15-17]. In 2009-2010, the prevalence of P.
vivax among malaria in children in Nouakchott repre-
sented 97.1% [18].
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vivax and other human malaria parasites is that only P.
vivax merozoites use the human Duffy antigen/chemo-
kine receptor (DARC) to invade red blood cells (RBCs)
[19-21]. The Duffy antigen was originally identified as a
blood group antigen on the surface of RBCs, but it has
since been found to be expressed in endothelial cells
and neurons [22-24]. It is implicated in multiple chemo-
kine inflammation, inflammatory diseases, and cancer
and might play a role in HIV infection [25-27]. The
DARC gene (also referred to as FY or Duffy), located on
chromosome 1, comprises two exons and produces a
protein that has a glycosylated external N-terminal
domain, seven transmembrane domains and a short
cytosolic C-terminal domain that is not coupled to G-
proteins or other known intracellular effectors [28-33].
DARC has two main variant forms, Fya and Fyb anti-
gens, which differ by a single amino acid (Gly42Asp) in
the NH2 extracellular domain of the polypeptide and are
encoded by the alleles FYA and FYB, respectively, which
are differentiated by a single base substitution (G125A)
[34-36]. The FYA/FYB frequency shows marked geo-
graphic disparities; the FYB allele is highly predominant
in Africa, while the FYA allele is dominant in Asia [37].
The Duffy blood group has four major phenotypes: Fy(a
+b
+), Fy(a
+b
-), Fy(a
-b
+)a n dF y ( a
-b
-). Duffy expression is
disrupted by a T to C substitution in the gene’s promo-
ter region at nucleotide -33, preventing the binding of
the h-GATA-1 erythroid transcription factor and result-
ing in the null expression of the Duffy gene in erythroid
cells only [38-40]. This variant is commonly associated
with the FYB allele (corresponding to the FYB
ES allele,
ES stands for “erythroid silent”), although the same
mutation has been detected and associated with the
FYA allele in individuals living in P. vivax-endemic
region of Papua New Guinea (FYA
ES) [41]. The FYB
ES
allele is almost fixed in West and Central Africa, and as
a consequence, the Fy(a
-b
-) (null) phenotype is predomi-
nant among populations of West and Central African
descent. This phenotype is rare among Caucasian,
Amerindian, Indian and Asian populations. The FYA
ES
mutation is rare and so far appears to be present only in
the Melanesian and Tunisian population) [41-44]. Other
rare variants have been described, most notably the FYX
allele, which occurs mainly in Caucasians [45,46] and is
characterized by a weak expression of Fyb antigen
(Fyb
weak).
Some authors [47-50] have attributed the FYX allele to
as i n g l ep o l y m o r p h i s mo ft h eFYB allele
(C265T®Arg89Cys) (FYX1), while others have indicated
two (C265T and G298A®Ala100Thr) (FYX2) [51-53] or
even three polymorphisms (C265T, G298A and G145T®
Ala49Ser) (FYX3) [54]. The point mutation G298A alone
did not cause a decrease of the Fyb expression [47]. This
allele is also named FYB* in the present study. Eight
combinations of alleles (FYA, FYB, FYB*, FYX [FYX1,
FYX2 and FYX3], FYA
ES and FYB
ES) result in 32 different
genotypes (Additional files 1 and 2).
Malaria therapy, as well as experimental and epide-
miological studies, have shown that erythrocyte Duffy
blood group negative individuals, mostly of African
ancestry, are resistant to P. vivax infection [21]. How-
ever, several reports have provided evidence for P. vivax
infections among Duffy-negative patients [55-59], sug-
gesting that there are P. vivax strains that have acquired
a Duffy-independent mechanism of erythrocyte invasion.
Little is known about the frequency of Duffy poly-
morphisms in Mauritanian populations, especially in P.
vivax-infected individuals. The objective of the present
study was to evaluate the Duffy blood group allelic and
genotype frequencies in the city of Nouakchott and to
compare these frequencies between P. vivax-infected
and uninfected febrile patients.
Methods
Study populations
This study was conducted in the capital and largest city
of Mauritania, Nouakchott, which is located on the
Atlantic coast of the Sahara Desert (18°.11’N; 16°.16’W).
The city is divided into nine districts and consists of
approximately 800,000 inhabitants. Nouakchott features
an arid climate with a short wet season extending from
July to September. The city has five hospitals and eleven
health centres. Between 2007 and 2009, Lekweiry et al
conducted a preliminary study on the incidence of
malaria in Nouakchott [17].
Capillary blood samples from 439 febrile outpatients
from all Nouakchott districts who were seen in the two
main hospitals of the city (National Hospital and Chiekh
Zayed Hospital) and in the District Health Center of
Teyarett were collected onto Whatman 3 MM filter
paper. A subset of 277 patients were enrolled in this
study to evaluate Duffy blood group. Of these 277
patients, 110 had a positive P. vivax diagnosis and 167
were not infected with Plasmodium but their individual
data on the place of residence and/or ethnic group
membership were available.
Consent
This study was reviewed and approved by the Maurita-
nian National Ethics Committee.
Genomic DNA extraction
Blood samples were spotted onto Whatman 3 MM filter
paper, dried, and stored at room temperature until use.
DNA was extracted with the MagMAX™-96 DNA
Multi-Sample Kit according to the manufacturer’s
instructions using a MagMAX™ Express-96 Magnetic
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France).
Identification of Plasmodium species by real-time PCR
Plasmodium detection was performed by real-time
LightCycler
® PCR (Roche, Meylan, France). The follow-
ing oligonucleotides primers and probes designed with
Primer Express software v2.0 (Applied Biosystems) were
used: forward-5’-TTTATGTATTGGTATAACATTC
GG-3’, reverse-5’-GGCAAATAACTTTATCATAGAAT
TGAC-3’ and probe-5’-FAM- TACACTACCAACACA
TGGGGCTACAAGAGGT-BBQ-3’ for P. falciparum
aquaglyceroporin gene (AJ413249); forward-5’-GTGG
CCGCCTTTTTGCT-3’, reverse-5’-CCTCCCTGAAACA
AGTCATCG-3’ and probe-5’-HEX- CATCTACGTGG
ACAACGGGCTCAACA-BHQ1-3’ for P. vivax enoyl-
acyl carrier protein reductase gene (AY423076); for-
ward- 5’-GAGGAATGGTCACCATGTAGTGT-3’,
reverse-5’-CAAATTTCAGTTTCAAGGTCACTTAA-3’
and probe-5’-HEX- ATTTTTTGCATCAACCTTTC
TTCTAGCCC -BHQ1-3’ for Plasmodium malariae cir-
cumsporozoïte gene (S69014); and forward-5’-CCAAG
CCCAGATAATAAGGAAGGT3’, reverse-5’-TTCGTGC
ACTTCAACTTACATTCAGT-3’ and probe-5’-FAM-
TTATTGTCCTCTGGGTTTGGAACTTTGCC-BBQ-3’
for P. ovale P25 ookinete surface protein gene
(AB074973) (Eurogentec, Angers, France). Each parasite
species was detected separately. Individual PCR amplifi-
cations were carried out using 4 μlo f5 ×c o n c e n t r a t e
Master Mix (LightCycler
® TaqMan
® Master, Roche), 0.8
μMo fe a c hp r i m e r ,0 . 1μM of probe and 5 μLo ft e m -
plate DNA in a final volume of 20 μL. The thermal
cycling conditions were 95°C for 10 min and 45 cycles
of 95°C for 10 sec and 60°C for 30 sec, followed by a
cooling step of 40°C for 30 sec. For each PCR run, two
negative controls (water and human DNA) and a posi-
tive control (DNA from each species) were used. Fluor-
escence acquisition was performed at the end of each
extension step.
Duffy blood group genotyping
Duffy blood group genotypes were assessed using PCR
amplification of the human Duffy antigen/chemokine
receptor gene (NG_011626.1) followed by sequencing.
The promoter region that flanks the GATA box motif
(a fragment of 392 bp) was amplified using the following
primers, which were designed with the NCBI/Primer-
BLAST online tool [60]:
forward-5’-CCCAAGGCCAGTGACCCCCATA-3’ and
reverse-5’-AGAGGGAGCTAGGAGGCTAGCAT-3’
(Eurogentec). To determine the Duffy RBC polymorph-
ism, a 541-bp fragment spanning part of intron and
exon 2 was amplified using the following primers (also
designed with the NCBI/Primer-Blast online tool [60]):
forward-5’-CCTGCAGAGACCTTGTTCTCCCAC-3’
and reverse-5’-AGCAGCAAAGCCTGGGCAAAGG-3’
(Eurogentec).
The reaction mixture for both PCR amplifications
included 10 μlo fg e n o m i cD N A ,2 . 5μl of 10× reaction
buffer (Eurogentec), 0.5 μM of each primer, 200 μMo f
deoxynucleoside triphosphate mixture (dGTP, dATP,
dTTP and dCTP) (Euromedex, Souffelweyersheim,
F r a n c e ) ,1 . 5m Mo fM g C l 2 and 2.5 units of RedGold-
Star
® DNA polymerase (Eurogentec) in a final volume
of 25 μL. The thermal cycler (T3 Biometra, Archamps,
France) was programmed as follows: an initial 94°C
incubation for 2 min followed by 40 cycles of 94°C for
30 sec, 58°C for 30 sec and 72°C for 25 sec for the pro-
moter region and 40 cycles of 94°C for 30 sec, 58°C for
30 sec and 72°C for 35 sec for the segment covering
part of intron and exon 2. A final 5-min extension step
was performed at 72°C for both regions. The PCR pro-
ducts were loaded on 1.5% agarose gel containing 0.5
μg/mL ethidium bromide. Amplicons were purified
using the QIAquick 96 PCR BioRobot Kit and an auto-
mated protocol on the BioRobot 8000 workstation (Qia-
gen, Courtaboeuf, France). The purified fragments were
sequenced using the BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems) using the primers
described above. The sequencing reaction products were
purified using the BigDye XTerminator
® Purification Kit
(Applied Biosystems) in accordance with the manufac-
turer’s instructions. The purified products were
sequenced using an ABI Prism 3100 analyser (Applied
Biosystems). Sequences were analysed using Vector NTI
advance™ software (version 11, Invitrogen, Cergy Pon-
toise, France).
Statistical analysis
Fisher’s exact test was used to compare the proportions
of Duffy genotypes in relation to P. vivax infection and
ethnic origin (GraphPad Prism v5.01). The significance
level was fixed at P < 0.05.
Results
Plasmodium species diagnosis
The results obtained by real-time PCR were in accor-
dance with the previous data obtained for species diag-
nosis (Malaria Rapid Diagnostic Test, microscopy and
nested PCR performed by [17]). Of 277 outpatients, 110
were positive for P. vivax. These patients came from
various Nouakchott districts (Additional file 3).
Duffy genotypes in febrile uninfected patients and P.
vivax-infected patients from Nouakchott
The promoter region and exon 2 of the Duffy gene from
each sample selected for the study were amplified and
sequenced (Additional file 3). A comparison of Duffy
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to the ethnic groups between P. vivax-infected and
malaria-free patients is presented in Tables 1 and 2. The
Moorish population represented the majority of patients
(83%). Only a few patients belonged to the other ethnic
groups: Poular (4%), Soninke (1%) and Wolof (1%).
Information on ethnic origin was not available for some
patients (11%), but these patients were included in the
study because they were positive for P. vivax.T h ec o m -
p l e t es e q u e n c eo ft h eD u f f yg e n ew a so b t a i n e df o r2 5 8
patients (93%).
I nt h eM o o r i s hp o p u l a t i o n ,t h ep r e v a l e n c er a t eo ft h e
FYB
ES/FYB
ES genotype (Fy(a
-b
-) phenotype) was 27.8%
(n = 40) and 0% among uninfected and P. vivax-infected
individuals, respectively (p < 0.0001, Fisher’se x a c tt e s t ) .
This was followed by a high level of FYA/FYB, FYB/
FYB, FYB/FYB
ES and FYA/FYB
ES genotype frequencies
(Fy(a
+b
+), Fy(a
-b
+), Fy(a
-b
+)a n dF y ( a
+b
-) phenotypes,
respectively) in both P. vivax-infected and uninfected
patients. Low frequencies were detected for the FYA/
FYA, FYA/FYB*, FYB*/FYB
ES and FYB/FYB* genotypes
(Fy(a
+b
-), Fy(a
+b+), Fy(a
-b
+)a n dF y ( a
-b
+)p h e n o t y p e s ,
respectively) in both infected and uninfected patients. In
the other ethnic groups (Poular, Soninke and Wolof),
only the FYB
ES/FYB
ES genotype was found in uninfected
patients, whereas the FYA/FYB
ES genotype was observed
in two P. vivax-infected patients, Soninke ethnic.
One P. vivax-infected patient presented the FYB
ES/
FYB
ES genotype, resulting in a Duffy-negative pheno-
type. This patient was a two-year-old female, belonging
to the Wolof ethnic group and living in the district of
Dar Naim.
Discussion
Recent reports on P. vivax infections suggest that this
parasite may be evolving and adapting to new epidemio-
logical contexts, becoming not only more virulent but
also more frequent in countries where the incidence has
traditionally been low [9-12,61,62]. The evaluation of
Duffy blood group polymorphisms is important in areas
where P. vivax prevails, as the Duffy antigen serves as a
receptor on the surface of RBCs. Until now, few studies
have reported the presence of P. vivax in Mauritania
[15,17,18,29,63] and only one study assessed the distri-
bution of Duffy polymorphisms in Nouakchott [64]. In
the present work, the evaluation of Duffy blood group
Table 1 Comparison of Duffy genotypes among uninfected and Plasmodium vivax-infected patients in ethnic groups
from Nouakchott, Mauritania.
ethnic
groups
Duffy number of uninfected patients No =
167 (%[95%CI])
number of P. vivax-infected patients No =
110 (%[95%CI])
p-value
genotypes predicted
phenotypes
Moor FYA/FYA positive 11 (7.6 [3.9-13.3]) 3 (3.8 [0.8-11.0]) 0.388
FYA/FYB positive 24 (16.6 [11.0-23.8]) 22 (28.6 [18.8-40.0]) 0.0548
FYA/FYB* positive 5 (3.5 [1.1-7.9]) 1 (1.3 [0.0-7.0]) 0.6674
FYA/FYB
ES positive 19 (13.2 [8.1-19.8]) 16 (20.8 [12.4-31.5]) 0.1757
FYB*/FYB
ES positive 0 (0) 1 (1.3 [0.0-7.0]) 0.3484
FYB/FYB positive 22 (15.3 [9.8-22.2]) 16 (20.8 [12.4-31.5]) 0.3504
FYB/FYB* positive 2 (1.4 [0.2-4.9]) 2 (2.6 [0.3-9.1]) 0.612
FYB/FYB
ES positive 21 (14.6 [9.3-21.4]) 16 (20.8 [12.4-31.5]) 0.2599
FYB
ES/FYB
ES negative 40 (27.8 [20.6-35.9]) 0 (0) <
0.0001
+
Poular FYB
ES/FYB
ES negative 8 (100) 0 (0) ND
Soninke FYA/FYB
ES positive 0 (0) 2 (100) 0.4667
FYB
ES/FYB
ES negative 2 (100) 0 (0) 0.4667
Wolof FYB
ES/
FYB
ES
negative 1 (100) 1 (100) ND
Unknown FYA/FYB positive 0 (0) 6 (26.1 [10.2-48.4]) ND
FYA/FYB* positive 0 (0) 1 (4.3 [0.1-21.9]) ND
FYA/FYB
ES positive 0 (0) 2 (8.7 [1.1-28.0]) ND
FYB/FYB positive 0 (0) 1 (4.3 [0.1-21.9]) ND
FYB/FYB
ES positive 0 (0) 13 (56.6 [34.5-76.8]) ND
ND ND ND 12 7 ND
+ Fisher’s Exact Test
ND: non determined
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populations that included P. vivax-infected, uninfected,
Duffy-positive and Duffy-negative people to i) assess the
Duffy gene polymorphism within a cosmopolitan Afri-
can community and ii) determine whether P. vivax is
able to penetrate into RBCs in Duffy-negative patients,
who have been thought to be resistant to P. vivax infec-
tion [21].
The Mauritanian population has a highly heteroge-
neous ethnic composition. It is primarily constituted of
Moors (an ethnicity with a mix of Arab and Berber
ancestry) who live in the North of the country and var-
ious black ethnic groups, including Soninke, Wolof and
Poular, in the South. Duffy gene polymorphism among
different ethnic groups is a characteristic of this blood
system and has been used as a marker of ethnic com-
position as well as an indicator of the evolution of
h u m a np o p u l a t i o n s .I n1 9 8 6 ,L e p e r set al undertook
the study of Duffy blood group in 107 individuals
belonging to different ethnic groups and residing in
Nouakchott [64]. In the overall population, 27% of the
individuals were Duffy-positive, whereas the others
were Duffy-negative. The proportion of Duffy- positive
individuals differed according to the ethnic groups:
54% of Moors were Fy
+, while only 2% of black ethnic
groups were Fy
+.
In the current study, slight differences were observed
in the global population: 78% of the individuals were Fy
+ and 22% were Fy
-.T h eFYA/FYB genotype was the
most common, followed by the heterozygotes FYA/
FYB
ES and FYB/FYB
ES and the homozygous FYB alleles.
It should be noted that no patient had the phenotype Fy
(a
+b
weak)o rF y ( a
-b
weak), as the allele FYX was not pre-
sent in the population.
When compared to other North African populations,
the frequencies of FYA and FYB alleles are similar to
that observed in the Tunisian people [44,65], while the
allelic frequency of FYB
ES and the lack of FYX are simi-
lar to what is observed in Morocco [66]. Overall, FYA
and FYB alleles are mainly represented in Europe, while
the allele FYB
ES is predominant in Africa [37].
T h ep r e s e n c eo fP. vivax in Mauritania was first
reported in 1948 [14] and confirmed in two recent stu-
dies suggesting autochthonous P. vivax transmission in
some patients who had never travelled outside Nouak-
chott [15,17]. RBCs of Duffy-negative individuals seem
to be naturally resistant to invasion by the P. vivax
human malaria parasite [21]. The present study
describes for the first time that one Duffy-negative
patient living in Nouakchott, i.e., in North Africa, was
infected with P. vivax. The identification of P. vivax was
performed by real-time PCR, and the Duffy genotypes
were determined by sequencing, making it unlikely that
a parasite other than P. vivax was involved.
Our data thereby confirmed the suspicion of some
authors, who also believe that P. vivax could be evolving
to use receptors other than Duffy to invade erythrocytes
in patients in Brazil [55,56], Kenya [59], and more
recently, in Madagascar [57], Angola and Equatorial Gui-
nea [58]. As suggested in previous studies [57,58], Duffy-
positive individuals may serve as reservoirs for P. vivax,
allowing this parasite to infect hepatocytes of Duffy-nega-
tive individuals and select for new P. vivax strains with
the capacity to invade Duffy-negative erythrocytes.
Conclusions
Further analyses are needed to understand the dynamics
of the Duffy gene and its possible contribution as a
Table 2 Comparison of allelic frequencies of the Duffy Blood Group System among uninfected and Plasmodium vivax-
infected patients in ethnic groups from Nouakchott, Mauritania.
ethnic groups Alleles Allelic frequencies (%[95%CI]) p-value
uninfected patients P. vivax-infected patients
Moor FYA 24.3 [19.5-29.7] 29.2 [22.2-37.1] 0.3058
FYB 31.6 [26.3-37.3] 46.8 [38.7-55.0] 0.0019
+
FYB* 2.4 [1.0-4.9] 2.6 [0.7-6.5] 1
FYB
ES 41.7 [35.9-47.6] 21.4 [15.2-28.8] < 0,0001
+
Poular FYB
ES 100 0 ND
Soninke FYA 0 100 ND
FYB
ES 100 0 0.0667
Wolof FYB
ES 100 100 ND
Unknown FYA 0 19.6 [9.4-33.9] ND
FYB 0 45.7 [30.9-61.0] ND
FYB* 0 21.7 [0.1-11.5] ND
FYB
ES 0 32.6 [19.5-48.0] ND
+ Fisher’s Exact Test
ND: non determined
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obtained in the present study emphasize the importance
of the evaluation of Duffy blood group genotypes in P.
vivax malaria endemic areas. The results of the present
study support the hypothesis that Duffy-negative indivi-
duals from North Africa could be infected by P. vivax
and that this parasite may be rapidly evolving to use
other receptors than Duffy to invade the erythrocytes.
Further longitudinal studies on P. vivax and host-para-
site interactions are required to test the validity of these
hypotheses. Furthermore, a better understanding of the
alternative pathways used by P. vivax to invade human
RBCs should become a research priority.
Additional material
Additional file 1: Duffy blood group nomenclature. Duffy alleles and
their corresponding genotype and phenotypic and expression.
Additional file 2: Phenotype expression relative to 32 different
genotypes possible from eight known Duffy alleles (FYA, FYB, FYB*,
FYX1, FYX2, FYX3, FYA
ES and FYB
ES).
Additional file 3: Individual data, Plasmodium diagnosis and Duffy
blood group genotypes for the patients selected in the study.
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